Loridon-Rosa B, Vielh P, Matsuura H, Clausen H, Cuadrado C, Burtin P
Laboratoire d'Anatomie Pathologique, CNRS, Villejuif, France.
Cancer Res. 1990 Mar 1;50(5):1608-12.
Two types of human fibronectin have been detected by the reactivity of specific monoclonal antibody FDC-6: (a) those present in normal plasma and adult tissues, which do not react with FDC-6 (normal fibronectin or norFN); and (b) those present in fetal tissues and in tumoral cell lines, which do react with FDC-6 (oncofetal fibronectin or onfFN) (H. Matsuura and S. I. Hakomori, Proc. Natl. Acad. Sci. USA, 82: 6517-6521, 1985). We compared the distribution of norFN and onfFN in normal breast tissue (15 samples), breast fibroadenoma (ten samples), and breast adenocarcinoma (80 samples), using an immunofluorescence technique with monoclonal antibody FDC-6. A polyclonal antiserum against human normal fibronectin was used as a control. While norFN was diffusely present in normal gland and in benign and malignant tumors, onfFN was absent in normal gland and in benign tumors. In carcinomas, however, its presence was frequent, as we found it in 60% of cases. Among classical prognosis factors in breast carcinomas, onfFN distribution was significantly correlated with histological grade. Indeed, the presence of FDC-6 labeling was significantly linked with intermediary and high malignancy grades, while its absence was significantly linked with low malignancy grade. onfFN could be considered a marker of the neoplastic state; its immunohistological detection may represent a new prognosis factor in breast carcinomas.
通过特异性单克隆抗体FDC-6的反应性检测到两种类型的人纤连蛋白:(a)存在于正常血浆和成人组织中的,不与FDC-6反应的(正常纤连蛋白或norFN);以及(b)存在于胎儿组织和肿瘤细胞系中的,与FDC-6反应的(癌胚纤连蛋白或onfFN)(H. Matsuura和S. I. Hakomori,《美国国家科学院院刊》,82: 6517 - 6521,1985)。我们使用单克隆抗体FDC-6的免疫荧光技术,比较了norFN和onfFN在正常乳腺组织(15个样本)、乳腺纤维腺瘤(10个样本)和乳腺腺癌(80个样本)中的分布。使用针对人正常纤连蛋白的多克隆抗血清作为对照。虽然norFN弥漫存在于正常腺体以及良性和恶性肿瘤中,但onfFN在正常腺体和良性肿瘤中不存在。然而,在癌组织中,其存在较为常见,我们在60%的病例中发现了它。在乳腺癌的经典预后因素中,onfFN分布与组织学分级显著相关。实际上,FDC-6标记的存在与中、高恶性分级显著相关,而其缺失与低恶性分级显著相关。onfFN可被视为肿瘤状态的标志物;其免疫组织学检测可能代表乳腺癌的一种新的预后因素。